| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Departments of Cardiovascular Medicine (N.U., M.O., H.Y., A.M., S.M., K.T., T.N., T. Takahashi, T. Tatsumi, H.M.) and Pharmacology (K.M.), Kyoto Prefectural University of Medicine; and Department of Pathology (Y.A.), Kansai Medical University, Osaka, Japan.
Correspondence to Mitsuhiko Okigaki, MD, Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-8566, Japan. E-mail okigakim{at}koto.kpu-m.ac.jp
We investigated whether the mobilization of endothelial progenitor cells (EPCs) by exogenous erythropoietin (Epo) promotes the repair of injured endothelium. Recombinant human Epo was injected (1000 IU/kg for the initial 3 days) after wire injury of the femoral artery of mice. Neointimal formation was inhibited by Epo to 48% of the control (P<0.05) in an NO-dependent manner. Epo induced a 1.4-fold increase in reendothelialized area of day 14 denuded vessels, 55% of which was derived from bone marrow (BM) cells. Epo increased the circulating Sca-1+/Flk-1+ EPCs (2.0-fold, P<0.05) with endothelial properties NO dependently. BM replacement by GFP- or ß-galactosidase-overexpressing cells showed that Epo stimulated both differentiation of BM-derived EPCs and proliferation of resident ECs. BM-derived ECs increased 2.2- to 2.7-fold (P<0.05) in the Epo-induced neoendothelium, where the expression of Epo receptor was upregulated. Epo induced Akt/eNOS phosphorylation and NO synthesis on EPCs and exerted an antiapoptotic action on wire-injured arteries. In conclusion, Epo treatment inhibits the neointimal hyperplasia after arterial injury in an NO-dependent manner by acting on the injured vessels and mobilizing EPCs to the neo-endothelium.
Key Words: restenosis endothelium progenitor cells erythropoietin
Related Article:
Circ. Res. 2006 98: 1341-1343.
This article has been cited by other articles:
![]() |
G. M. T. Hare, A. K. Y. Tsui, A. T. McLaren, T. E. Ragoonanan, J. Yu, and C. D. Mazer Anemia and Cerebral Outcomes: Many Questions, Fewer Answers Anesth. Analg., October 1, 2008; 107(4): 1356 - 1370. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Surdacki, E. Marewicz, E. Wieteska, G. Szastak, T. Rakowski, E. Wieczorek-Surdacka, D. Dudek, J. Pryjma, and J. S. Dubiel Association between endothelial progenitor cell depletion in blood and mild-to-moderate renal insufficiency in stable angina Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2265 - 2273. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. d'Uscio and Z. S. Katusic Erythropoietin Increases Endothelial Biosynthesis of Tetrahydrobiopterin by Activation of Protein Kinase B{alpha}/Akt1 Hypertension, July 1, 2008; 52(1): 93 - 99. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zampetaki, J. P. Kirton, and Q. Xu Vascular repair by endothelial progenitor cells Cardiovasc Res, June 1, 2008; 78(3): 413 - 421. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. van Albada, G. J. du Marchie Sarvaas, J. Koster, M. C. Houwertjes, R. M. F. Berger, and R. G. Schoemaker Effects of erythropoietin on advanced pulmonary vascular remodelling Eur. Respir. J., January 1, 2008; 31(1): 126 - 134. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Reddy, J. K. Vasir, G. V. Hegde, S. S. Joshi, and V. Labhasetwar Erythropoietin Induces Excessive Neointima Formation: A Study in a Rat Carotid Artery Model of Vascular Injury Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 237 - 247. [Abstract] [PDF] |
||||
![]() |
B. D. Westenbrink, E. Lipsic, P. van der Meer, P. van der Harst, H. Oeseburg, G. J. Du Marchie Sarvaas, J. Koster, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization Eur. Heart J., August 2, 2007; 28(16): 2018 - 2027. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Lee, J. S. Lee, and J. Y. Lee Prevention of Erythropoietin-Associated Hypertension Hypertension, August 1, 2007; 50(2): 439 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Chen, S.-J. Lin, F.-Y. Lin, T.-C. Wu, C.-R. Tsao, P.-H. Huang, P.-L. Liu, Y.-L. Chen, and J.-W. Chen High Glucose Impairs Early and Late Endothelial Progenitor Cells by Modifying Nitric Oxide-Related but Not Oxidative Stress-Mediated Mechanisms Diabetes, June 1, 2007; 56(6): 1559 - 1568. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Balasubramaniam, C. F. Mervis, A. M. Maxey, N. E. Markham, and S. H. Abman Hyperoxia reduces bone marrow, circulating, and lung endothelial progenitor cells in the developing lung: implications for the pathogenesis of bronchopulmonary dysplasia Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1073 - L1084. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. d'Uscio, L. A. Smith, A. V. Santhanam, D. Richardson, K. A. Nath, and Z. S. Katusic Essential Role of Endothelial Nitric Oxide Synthase in Vascular Effects of Erythropoietin Hypertension, May 1, 2007; 49(5): 1142 - 1148. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Madeddu and C. Emanueli Switching on Reparative Angiogenesis: Essential Role of the Vascular Erythropoietin Receptor Circ. Res., March 16, 2007; 100(5): 599 - 601. [Full Text] [PDF] |
||||
![]() |
T. F. Luscher, J. Steffel, F. R. Eberli, M. Joner, G. Nakazawa, F. C. Tanner, and R. Virmani Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications Circulation, February 27, 2007; 115(8): 1051 - 1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Kiernan and R. D. Simari Vasculoprotective Effects of Erythropoietin: New Developments and New Alternatives Circ. Res., June 9, 2006; 98(11): 1341 - 1343. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |